Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin

Polycystic ovary syndrome (PCOS) and hypothyroidism are related conditions, and both are associated with adverse pregnancy outcomes. Knowledge is lacking about the complex interaction between thyroid status and PCOS during pregnancy. We investigated the thyroid status and its association with pregna...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2022-02, Vol.13, p.772801-772801
Main Authors: Trouva, Anastasia, Alvarsson, Michael, Calissendorff, Jan, Åsvold, Bjørn Olav, Vanky, Eszter, Hirschberg, Angelica Lindén
Format: Article
Language:English
Subjects:
Diabetes, Gestational - drug therapy
Diabetes, Gestational - epidemiology
Endocrinology
Female
Humans
hypothyroidism
Hypothyroidism - chemically induced
Hypothyroidism - drug therapy
Hypothyroidism - epidemiology
Medicin och hälsovetenskap
metformin
Metformin - adverse effects
Metformin - therapeutic use
PCOS (polycystic ovarian syndrome)
Pilot Projects
Polycystic Ovary Syndrome - complications
Polycystic Ovary Syndrome - drug therapy
Pregnancy
Pregnancy Complications - drug therapy
Pregnancy Complications - epidemiology
Pregnancy Outcome
Thyrotropin
Weight Gain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycystic ovary syndrome (PCOS) and hypothyroidism are related conditions, and both are associated with adverse pregnancy outcomes. Knowledge is lacking about the complex interaction between thyroid status and PCOS during pregnancy. We investigated the thyroid status and its association with pregnancy complications in PCOS, and in relation to metformin treatment. analyses of two randomized, double-blind, placebo-controlled trials. 288 pregnant women with PCOS were randomized to treatment with metformin or placebo from first trimester to delivery. We measured serum levels of thyroid stimulating hormone (TSH) and free thyroxine (fT4) at gestational week (gw) 5-12, 19, 32 and 36 and related to metformin treatment and pregnancy complications. Thyroid peroxidase antibodies (TPO-ab) were analyzed at inclusion and at gw 36. The overall prevalence of subclinical and overt hypothyroidism was 1.5% and 0%, respectively. The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.772801